Retatrutide and GLP-1 research explainers and weekly peptide news.https://retarate.com/https://retarate.com/blog/fda-interim-peptide-compounding-policy-white-house-review/https://retarate.com/blog/fda-interim-peptide-compounding-policy-white-house-review/FDA has sent an interim peptide compounding policy to White House review. What it may cover, what it excludes, and why retatrutide isn't part of it.Mon, 19 Oct 2026 00:00:00 GMThttps://retarate.com/blog/glp-1-vs-dual-vs-triple-agonists/https://retarate.com/blog/glp-1-vs-dual-vs-triple-agonists/Semaglutide, tirzepatide and retatrutide compared: how single, dual and triple incretin agonists work, what trials found, and what is still unknown.Thu, 15 Oct 2026 00:00:00 GMThttps://retarate.com/blog/retatrutide-clinical-trial-results-explained/https://retarate.com/blog/retatrutide-clinical-trial-results-explained/Every major retatrutide trial in one place: phase 2 NEJM data, TRIUMPH-1 to TRIUMPH-4, TRANSCEND-T2D-1, side effects and the FDA timeline.Mon, 12 Oct 2026 00:00:00 GMT